Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis
Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
180 participants
May 22, 2025
INTERVENTIONAL
Conditions
Summary
The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.
Eligibility
Inclusion Criteria3
- Age: 0-65 years old, diagnosed with sepsis
- Clinical diagnosis of sepsis (based on Sepsis 3.0 International Guidelines)
- Confirmed or suspected infection
Exclusion Criteria13
- Violation of medical ethics
- Significant confounding factors likely to bias study outcomes
- Poor adherence to the study protocol
- Concurrent participation in other clinical trials
- Specific medical conditions:
- History of chronic enteritis, neuropsychiatric disorders, or transplantation (bone marrow, lung, liver, pancreas, or small intestine)
- Severe primary diseases affecting survival (e.g., life-limiting hepatic, renal, or endocrine disorders) or psychiatric disorders
- History of hypersensitivity or severe adverse reactions to biological products
- Imminent terminal status (e.g., septic shock, life expectancy <7 days)
- Foreseeable risk of medical errors or disputes during hospitalization
- Active drug-resistant infections
- History of malignancy at screening
- Pregnancy, lactation, or plans for pregnancy within the next year
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
45 patients are infused with equal volume of control solution and receive regulatory treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06882811